SCEMBLIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SCEMBLIX (SCEMBLIX).
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6; minor contribution from CYP2C8, CYP2C9, and CYP2C19. |
| Excretion | Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing. |
| Protein binding | Approximately 97% bound to plasma proteins (primarily albumin and alpha-1 acid glycoprotein). |
| Volume of Distribution | Apparent Vd of 1320 L (≈18.9 L/kg for 70 kg). Extensive tissue distribution. |
| Bioavailability | Absolute bioavailability not established; oral absorption is rapid with peak plasma concentrations at 2–5 h. High-fat meal decreases Cmax by 30% and AUC by 25%. |
| Onset of Action | Oral administration: BCR-ABL1 inhibition occurs within hours; clinical response (e.g., hematologic improvement) typically evident within 2–4 weeks. |
| Duration of Action | Trough concentrations maintain target inhibition over 24 h with once-daily dosing. Continuous therapy required for sustained response. |
| Molecular Weight | 549.6 |
200 mg orally once daily with a meal.
| Dosage form | TABLET |
| Renal impairment | For GFR ≥60 mL/min: no adjustment. For GFR 30-59 mL/min: reduce dose to 100 mg once daily. For GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; monitor renal function more frequently due to age-related decline. |
| 1st trimester | Avoid use due to potential embryotoxicity and teratogenicity based on animal studies. Human data are lacking. |
| 2nd trimester | Avoid use; limited human data but animal studies show fetal harm. Consider risk vs benefit. |
| 3rd trimester | Avoid use; may cause fetal harm. Use only if maternal benefit outweighs fetal risk. |
Clinical note
Comprehensive clinical and safety monograph for SCEMBLIX (SCEMBLIX).
| Placental transfer | Likely crosses placenta based on molecular weight and animal studies demonstrating fetal exposure. |
| Breastfeeding | No data on presence in human milk. Due to potential for serious adverse reactions in nursing infants, advise against breastfeeding during treatment and for at least 2 weeks after last dose. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to asciminib or any excipientsConcurrent use with strong CYP3A4 inducers
| Precautions | Cardiovascular adverse reactions (arrhythmias, hypertension), Pancreatitis, Fluid retention (pleural effusion, pericardial effusion), Hepatotoxicity, Myelosuppression, Embryo-fetal toxicity |
| Food/Dietary | Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) as they inhibit CYP3A4 and may increase asciminib plasma concentrations. SCEMBLIX can be administered with or without food. No specific food restrictions otherwise, but a high-fat meal may slightly increase absorption (not clinically significant). |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | In animal studies, SCEMBLIX (asciminib) caused embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below the human exposure at the recommended dose. There are no adequate and well-controlled studies in pregnant women. Based on mechanism of action, may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. First trimester: highest risk for major malformations. Second and third trimesters: risk of fetal growth restriction and adverse effects on fetal development. |
| Fetal Monitoring | Monitor for myelosuppression with complete blood counts every two weeks for the first three months, then monthly. Monitor pancreatic enzymes (lipase and amylase) every four weeks. Monitor blood pressure and heart rate at baseline and periodically. Assess for signs of bleeding, infection, and fluid retention. In pregnancy, monitor fetal growth by ultrasound if exposure occurs. |
| Fertility Effects | Based on animal studies, SCEMBLIX may impair female and male fertility. In male rats, reduced sperm count and motility observed at clinically relevant exposures. In female rats, reduced fertility and increased preimplantation loss. Reversibility not established. |
| Clinical Pearls |
| SCEMBLIX (asciminib) is a BCR-ABL1 inhibitor specifically targeting the myristoyl pocket (STAMP inhibitor). It is indicated for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs) or with T315I mutation. Monitor pancreatic enzymes due to risk of pancreatitis; lipase and amylase should be checked monthly for the first 2 months then as clinically indicated. Also monitor for arterial thrombotic events, especially in patients with cardiovascular risk factors. Dose adjustment required with strong CYP3A4 inhibitors; avoid concomitant use with strong CYP3A4 inducers. SCEMBLIX can be taken with or without food. |
| Patient Advice | Take SCEMBLIX exactly as prescribed; swallow tablets whole with water; do not crush or split. · Avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase drug levels. · Report any new or worsening abdominal pain, nausea, vomiting, or back pain promptly as these may indicate pancreatitis. · Tell your doctor if you have a history of heart attack, stroke, or blood clots; SCEMBLIX may increase risk. · Do not take any other medications (prescription, OTC, herbal) without consulting your healthcare provider due to potential interactions. · Attend all scheduled blood tests to monitor pancreas function and blood counts. · If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose. · Use effective contraception during treatment and for at least 1 week after the last dose if you or your partner can become pregnant. |